TARS Company Profile and Key Details

TARS has shown weak momentum, losing -6.09% over the past week and -2.74% over the past quarter, though year-to-date performance is down -13.37%. Short-term trend indicators are bearishly aligned (SMA20 -9.74%, SMA50 -9.25%, SMA200 22.98%). The stock’s 14-day RSI is 25.47 (weak momentum), while the ATR of 3.04 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -16.8% below its high and over 84.19% above its low. Average 10-day trading volume of 577.16 thousand shares is slightly above the 3-month average of 497.53 thousand, indicating heightened recent market interest.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) closed at $71.17 USD, gaining $0.24 (0.34%) from the previous close of $70.93. The stock is currently mid-range between its 52-week high and low $38.51 and $85.25. With a market capitalization of about $3.02 billion, Tarsus Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.60). Key stats such as the average daily volume over the past year has been around 555.34 thousand shares, in line with its 52-week average. Headquartered in Irvine, CA, Tarsus Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bobak R. Azamian, the company employs approximately 323 people and listed since October 16, 2020. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.

Tarsus Pharmaceuticals, Inc. has 42.21 million shares outstanding. The public float is 30.35 million shares, elevated short interest at 17.98% of float. This equals 7.34 million shares. The short ratio is 10.79 days. Institutional investors hold 114.53% of the float. Insiders own 3.04%. Azamian Bobak R. holds 857.99 thousand shares, Neervannan Seshadri has 79.68 thousand shares and Wahl Bryan has 51.71 thousand shares. Over the past six months, insider transactions show net selling. They sold 54.81 thousand shares across 8 transactions.

Tarsus Pharmaceuticals, Inc. generated EPS of -$2.01 over the past year. Five-year average earnings growth is -67.97%. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.09. Next year's EPS is expected at -$2.67. Analyst sentiment is bullish. Analyst rating data shows there are 5 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $100.00 to $58.00. The high target offers 40.98% upside. The low target suggests -18.23% downside. The mean target is $77.80. This offers 9.69% upside. Tarsus Pharmaceuticals, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended November 04, 2025, missed forecasts by -14.29%. The prior quarter beat by 45.45%. Over the last six quarters, Apple has recorded several small beats. These include -10.2% in August 08, 2024.

Tarsus Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$37.68. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Tarsus Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -11.01%, with price expected at $63.12 by February 03, 2026, within a range of $61.46 to $64.86 3-Month Outlook: Projected fall of -16.02%, reaching $59.57 by April 16, 2026, with a range of $54.47 to $63.90. 1-Year Outlook: Projected gain of 32.36%, with price at $93.88 by January 15, 2027, within a range of $90.77 to $97.06.

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares are down -13.37% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Tarsus Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -36.89. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $58.33, suggesting -17.76% downside. Our AI forecast model points to short-term weakness (-11.01% over two weeks), a medium-term fall (-16.02% over three months), and a longer-term gain (32.36% over one year), with expected trading ranges indicating moderate volatility.

Tarsus Pharmaceuticals, Inc. trades at a P/E ratio of -36.89, slightly below the S&P 500 average, with a price-to-sales ratio of 8.15 and a price-to-book ratio of 8.93 trading at moderately above to book value. The P/FCF stands at -47.69, also below market averages.